F. Amanat

Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination

This study identifies non-neutralizing antibodies from vaccinated individuals that protect against SARS-CoV-2 in animal models, highlighting their role through Fc-mediated effector functions and conserved epitope binding.

Immunity to seasonal coronavirus spike proteins does not protect from SARS-CoV-2 challenge in a mouse model but has no detrimental effect on protection mediated by COVID-19 mRNA vaccination

This study investigates whether immunity to seasonal coronavirus spike proteins protects against SARS-CoV-2 in mice and affects mRNA vaccine efficacy, finding no increased protection but no detrimental effect on vaccination.

Environmental filtering and habitat (mis)matching of riverine invertebrate metacommunities

This study examines environmental filtering and habitat matching in riverine macroinvertebrate communities across nine U.S. ecoregions, finding variation in their drivers and predictors.

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles

This study compares the Fc-functional antibody profiles of mRNA-1273 and BNT162b2 vaccines in a cohort of hospital staff, finding differences in epitope-specific responses and effector functions.

Vaccination with B.1.1.7, B.1.351 and P.1 variants protects mice from challenge with wild type SARS-CoV-2

This study evaluates cross-neutralizing antibody responses and protective efficacy of vaccines based on SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 in mice against wild type SARS-CoV-2 challenge.

Structure of a germline-like human antibody defines a neutralizing epitope on the SARS-CoV-2 spike NTD

The paper structures a germline-like antibody in complex with SARS-CoV-2 spike NTD, revealing a neutralizing epitope and its conservation across variants.

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamsters

This study develops a Newcastle disease virus-based vaccine expressing a prefusion-stabilized SARS-CoV-2 spike protein, showing strong immune responses and cross-neutralization against variants in mice and hamsters.

Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner

This study evaluates murine monoclonal antibodies against SARS-CoV-2 RBD, showing neutralization of wild-type and variants, and in vivo protection dependent on neutralization.

A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants

A vaccine-induced human monoclonal antibody neutralizes SARS-CoV-2 and variants, reducing lung inflammation and viral load in hamsters.

Monoclonal antibodies targeting the influenza virus N6 neuraminidase

This study generates and characterizes monoclonal antibodies against the N6 neuraminidase subtype of influenza viruses, showing broad reactivity and antiviral activity, but limited inhibition of H5N6 NA.

Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination

This study shows that NVX-CoV2373 vaccine induces antibodies with both neutralizing and Fc-effector functions, which together provide maximal protection against SARS-CoV-2 in non-human primates.

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques

This study shows intranasal ChAdOx1 nCoV-19 vaccination reduces SARS-CoV-2 shedding in animal models but not pneumonia protection.

Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus

The paper functionally and antigenically characterizes the hemagglutinin and neuraminidase of Wuhan spiny eel influenza virus to assess its status as a bona fide influenza virus.

Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine

This paper demonstrates that a novel TLR7/8 agonist adjuvant enables single-shot protection against SARS-CoV-2 and influenza in mice using recombinant spike protein and inactivated vaccines.

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse model

This study shows that deleting the polybasic cleavage site and introducing proline mutations in the SARS-CoV-2 spike protein enhances vaccine efficacy in a mouse model.

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine

This paper evaluates an inactivated Newcastle disease virus expressing the SARS-CoV-2 spike protein as a cost-effective vaccine, showing immunogenicity and protective efficacy in animal models.

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate

This paper describes NDV vector vaccines expressing SARS-CoV-2 spike protein that protect mice from viral challenge and can be produced cost-effectively in chicken eggs.

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection

This study compares two SARS-CoV-2 infection models in mice: K18-hACE2 transgenic and adenovirus-mediated hACE2 delivery, showing differences in viral replication and disease outcomes.